CVKD

Cadrenal Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website cadrenal.com
Employees(FY) 3
ISIN US1276362076

Performance

-18.22%

-15.99%

+140.4%

+135.2%

+30.65%

YTD

+87.7%

Profile

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Advanced Technical Analysis

Technical Analysis of CVKD 2024-11-20

The stock indicators reflect a predominantly neutral sentiment, with the Moving Average Score at 43, the Oscillators Score at 36, and the overall Technical Score at 40. While the Moving Average suggests a slight bullish inclination, the Oscillators indicate bearish pressure, resulting in a cautious outlook for the stock.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of CVKD

Stock Rank

Recent News & Updates

2024-11-18 20:00
Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook(Prnewswire)
2024-11-11 20:00
CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS(Prnewswire)
2024-11-06 20:00
CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE(Prnewswire)
2024-11-01 08:00
Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds(Prnewswire)
2024-10-23 21:00
Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility(Prnewswire)
2024-10-22 21:00
CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM(Prnewswire)
2024-09-23 04:15
Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference(Prnewswire)
2024-09-11 01:00
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing(Accesswire)
2024-08-21 21:00
Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients(Prnewswire)
2024-08-20 19:00
Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now(Globenewswire)
2024-08-19 21:00
Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients(Prnewswire)
2024-08-19 19:00
Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now(Globenewswire)
2024-08-13 21:00
Cadrenal Therapeutics to Present at Upcoming Investor Conferences(Prnewswire)
2024-08-12 05:07
Cadrenal Therapeutics, Inc. (CVKD): A New Penny Stock to Buy Now(Yahoo Finance)
2024-08-07 11:53
CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q2 2024(Investorplace)
2024-08-07 04:05
Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update(Prnewswire)
2024-08-05 21:00
Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs(Prnewswire)
2024-07-16 21:00
Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024(Prnewswire)
2024-07-16 19:00
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now(Globenewswire)
2024-07-15 19:00
Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now(Globenewswire)
2024-06-11 19:00
Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now(Globenewswire)
2024-06-11 04:15
Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024(Prnewswire)
2024-06-10 19:00
Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now(Globenewswire)
2024-06-02 21:00
Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients(Prnewswire)
2024-05-22 21:00
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024(Prnewswire)
2024-05-09 01:53
CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q1 2024(Investorplace)
2024-05-08 21:00
Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update(Prnewswire)
2024-04-11 04:30
Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024(Prnewswire)
2024-04-08 21:00
Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts(Prnewswire)
2024-03-10 21:00
Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update(Prnewswire)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.